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Accepted 21 August 2015; Published online 28 September 2015AbstractObjective: To further evaluate the higher order measurement structure of the European Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), with the aim of generating a summary score.
Study Design and Setting: Using pretreatment QLQ-C30 data (N 5 3,282), we conducted confirmatory factor analyses to test seven
previously evaluated higher order models. We compared the summary score(s) derived from the best performing higher order model with
the original QLQ-C30 scale scores, using tumor stage, performance status, and change over time (N 5 244) as grouping variables.
Results: Although all models showed acceptable fit, we continued in the interest of parsimony with known-groups validity and respon-
siveness analyses using a summary score derived from the single higher order factor model. The validity and responsiveness of this QLQ-
C30 summary score was equal to, and in many cases superior to the original, underlying QLQ-C30 scale scores.
Conclusion: Our results provide empirical support for a measurement model for the QLQ-C30 yielding a single summary score. The
availability of this summary score can avoid problems with potential type I errors that arise because of multiple testing when making
comparisons based on the 15 outcomes generated by this questionnaire and may reduce sample size requirements for health-related
quality of life studies using the QLQ-C30 questionnaire when an overall summary score is a relevant primary outcome.  2016
The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Patient-reported outcome measures (PROMs) are
currently seen as important outcomes in both observational
studies and clinical trials. They represent the patients’ voice
in determining the burden of disease and its treatment. OneFunding: The work of J.M.G. was supported by a grant from the
Austrian Science Fund (FWF J3353).
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http://dx.doi.org/10.1016/j.jclinepi.2015.08.007
0895-4356/ 2016 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).of the most widely used PROMs in oncology is the Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire Core 30 (QLQ-
C30) [1]. The QLQ-C30 is a multidimensional health-
related quality of life (HRQOL) questionnaire composed
of six functional scales, three symptom scales, and a num-
ber of additional single item scales (15 outcomes, in total).
Although the QLQ-C30 provides a wealth of informa-
tion about the HRQOL of patients, it also presents an ana-
lytic challenge because of the multiple outcomes it
generates, and the concomitant risk of committing a type
I error due to multiple testing [1,2]. In some studies, it isess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 We found a robust single higher order factor model
to be the best performing measurement model for
the European Organisation for Research and Treat-
ment of Cancer (EORTC) Quality of Life Ques-
tionnaire Core 30 (QLQ-C30).
 The resulting QLQ-C30 summary score exhibits
equal or superior known-groups validity and
responsiveness to change over time as compared
to the individual QLQ-C30 scales.
What this adds to what was known?
 The results support the robustness of a single-
factor higher order measurement model for the
QLQ-C30.
 The validity and responsiveness of the QLQ-C30
summary score is equal to, and in many cases su-
perior to the original, underlying QLQ-C30 scale
scores.
What is the implication and what should change
now?
 The EORTC Quality of Life Group recommends
using the QLQ-C30 summary score to supplement
the 15-outcome profile generated by the QLQ-C30.
 The availability of a summary score can facilitate
more reliable hypothesis testing analyzing QLQ-
C30 data.
 If the QLQ-C30 summary score is chosen as the
primary focus of a study, then its use can reduce
the risk of type I errors that can occur when mak-
ing comparisons based on the original 15 outcomes
generated by the QLQ-C30. Thus, it may be
possible to reduce sample size requirements for
health-related quality of life studies using the
QLQ-C30 questionnaire.
possible to reduce the number of statistical tests performed
by defining a limited set of QLQ-C30 scales that are of
primary interest. Preferably this is done on an a priori basis
to avoid selective, post-hoc reporting of results [3,4]. How-
ever, in many studies, it may be difficult to prespecify
which QLQ-C30 scales are of most interest. In such cases,
investigators frequently rely on the two-item scale assess-
ing overall quality of life [5e8].
The disadvantage of this very brief two-item overall
quality of life scale is that it may have less measurement
precision than is desired for detecting group differences
over time. In addition, it may not be a conceptually
80 J.M. Giesinger et al. / Journal of Cappropriate summary of the QLQ-C30, which contains a
relatively large number of symptom scales and items [9,10].
On the basis of such considerations, Hinz et al. and
Nordin et al. introduced and investigated summary scores
for the QLQ-C30. Hinz et al. [11] used a total score derived
from summing up all 30 items of the questionnaire and two
separate summary scores based on the sum of all items of
the functioning domains and of the symptom domains,
respectively. Nordin et al. [12] investigated the known-
groups validity of the two-item global quality of life scale
and three alternative scoring algorithms for the QLQ-C30
based on (1) the 15 QLQ-C30 scale means; (2) the sum
of all individual QLQ-C30 items (except for the item on
financial problems); and (3) the sum of the scales assessing
physical function, emotional function, quality of life, fa-
tigue, nausea/vomiting, pain, appetite, and diarrhea. For
all proposed summary measures, change was categorized
in one way or the other into improved, unchanged, and
worse. The three alternative scoring approaches performed
considerably better than the original, two-item quality of
life scale. Although this study documented that the QLQ-
C30 global quality of life scale may not be particularly well
suited for detecting changes between patient groups and/or
changes over time, the alternative summary scoring algo-
rithms proposed were generated in an ad hoc manner,
without rigorous empirical testing of hypothesized mea-
surement models.
Cognizant of the need to have a solid empirical basis for
any proposed higher summary score for the QLQ-C30,
Gundy et al. [10] used structural equation modeling to test
seven alternative higher order measurement models for the
QLQ-C30. All models exhibited a moderate-to-good
model-data fit. The model that showed the best statistical
fit (slightly better that the other models) was a two-factor
model of physical and mental health. This is conceptually
similar to the SF-36 Health Survey component scores,
and the factor structure of the PROMIS domain mapping
project [10,13e16] Although appealing conceptually,
Gundy et al. questioned if this advantage outweighs the
model’s relatively complex nature, and if perhaps a more
parsimonious and simpler model would be more suitable.
The aims of the present study were to (1) identify the
best performing higher order model among those suggested
by Gundy et al. [10]; (2) test the validity and responsiveness
of the best performing higher order factor score(s) as
compared to that of the underlying individual scales of
the QLQ-C30; and (3) develop an additional scoring algo-
rithm for summary score(s) for the QLQ-C30 on the basis
of a higher order measurement model.2. Methods
2.1. Data source
The QLQ-C30 data used for these analyses were
collected originally for the EORTC Quality of Life Cross-
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jclinepi.com) and have been described in detail elsewhere
[10,17,18]. Briefly, the pooled database was formed from
124 individual data sets from 48 countries. In addition to
the QLQ-C30, the data set also incorporated patient and
clinical characteristics, including age, sex, country, lan-
guage of administration, primary disease site, and stage
of disease. The database consisted of 38,000 respondents,
of whom more than 30,000 completed baseline (pretreat-
ment) questionnaires. Of these 30,000 respondents, 9,044
completed the most recent version (3.0) of the QLQ-C30
[10]. For their study, Gundy et al. [10] selected a 50%
random sample of the 9,044 respondents who completed
the QLQ-C30, version 3.0. In the present study, we used
the remaining 50% of that sample but restricted ourselves
to those patients for whom tumor stage was known
(N 5 3,282). For the longitudinal analysis, we included pa-
tients for whom both pretreatment and on-treatment QLQ-
C30 data and information on the type of treatment received
were available (N 5 811).
2.2. The EORTC QLQ-C30
The 30-item EORTC QLQ-C30 version 3.0 [1,2] con-
sists of five multi-item function scales (physical [PF], role
[RF], cognitive [CF], emotional [EF], and social [SF]),
three multi-item symptom scales (fatigue [FA], nausea
and vomiting [NV], and pain [PA]), six single-item symp-
tom scales (dyspnea [DY], insomnia [SL], appetite loss
[AP], constipation [CO], diarrhea [DI], and financial impact
[FI]), and a two-item global quality of life scale (QL).
The questionnaire has a 1-week time frame and uses a
four-point response format (‘‘not at all,’’ ‘‘a little,’’ ‘‘quite
a bit,’’ and ‘‘very much’’), with the exception of the global
QL scale, which has a seven-point response format. For the
functioning and the QL scales, a higher score indicates bet-
ter health. For the symptoms scales, a higher score indicates
a higher level of symptom burden.
2.3. Models tested
In the current analysis, we tested the seven HRQOL
higher order measurement models evaluated by Gundy
et al. [10]. For a graphical representation of the models,
see Fig. 1.
(1) The Standard 14 dimensional QLQ-C30 model, the
original measurement model of the QLQ-C30, which
formed the basis for all of the other models described
here.
(2) The two-factor, Physical health and Mental health
model, in which the original QLQ-C30 scales RF,
SF, FA, PA, and SL load on both the mental as well
as the physical higher order factor. The remaining
scales load only on the physical higher order factor
(PF, NV, DY, AP, CO, and DI scale) or on the mental
higher-order factor (EF and CF scale).(3) The Physical burden and Mental function model, in
which PF, FA, NV, PA, DY, SL, AP, CO, and DI load
on the Physical burden factor. The functional scales
EF and CF load on the Mental function factor, and
RF and SF load on both factors.
(4) The Symptom burden and Function model [19], in
which PF, SF, RF, CF, and EF load on Function,
and FA, NV, PA, DY, SL, AP, CO, and DI load on
Burden.
(5) The one-factor HRQOL model [20], in which all orig-
inal QLQ-C30 scales (with the exception of the QL
scale) load on HRQOL.(6) & (7) The Formative Symptom burden and Function
model [21,22], in which FA, NV, PA, DY, SL, AP, CO,
and DI function are seen as formative indicators of
Burden, and PF, SF, RF, CF, and EF function as reflec-
tive indicators of Function. In model 6, the weights of
the formative scales are estimated freely, and in
model 7, they are fixed to 1.0.
In all the previously mentioned models, FI is omitted,
and the QL scale is correlated with, but not subsumed by
any higher order factor. This is in line with the approach
followed by Gundy et al. [10]. However, for completeness,
we also show in Fig. 1 an 8th modelda one-factor model
using all 30 items of the QLQ-C30.2.4. Statistical analyses
Descriptive statistics were used to characterize the
sample in terms of sociodemographic and clinical vari-
ables. For replication purposes, the modeling procedures
were identical to those used in the study of Gundy et al.
[10]. In short, we used pretreatment QLQ-C30 data and
carried out higher order confirmatory factor analyses
(CFAs) in Mplus, version 6.12 [23]. We modeled the orig-
inal QLQ-C30 subscales as first-order factors. The QL
scale was also modeled as a first-order factor and was al-
lowed to correlate with all other higher order factors but
remained distinct from them. To be able to identify the
models, we fixed one of the item loadings to a value of
1.0. Both loadings of items corresponding to the QL latent
variable were also fixed. As in the study of Gundy et al.
[10], we fixed the residual variances for the single-item
first-order factors to be equal, at 20% of the total variance
for these factors, on the basis of testeretest correlations
reported elsewhere [24].
We used pair-wise deletion, and a weighted least squares
estimator with adjustment for means and variance, which
takes into account deviations from normality [25,26]. To
test goodness of fit, we used the Comparative Fit Index
and the Tucker-Lewis Index. For both, values 0.95 indi-
cate a good fit, and values O0.90 an acceptable fit [27].
We also used the Root Mean Square Error of Approxima-
tion as an indicator of model fit, with values !0.05 indi-
cating a good fit, and between 0.05 and 0.08 an
Fig. 1. Higher order models for the EORTC QLQ-C30 (models 1e7 was taken from Gundy et al., model 8 was created ad hoc). AP, appetite loss; CF,
cognitive function; CO, constipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC QLQ-C30, European Organisation for Research and
Treatment of Cancer, Quality of Life Questionnaire Core 30; FA, fatigue; FI, financial impact; HRQOL, health-related quality of life; NV, nausea and
vomiting; PA, pain; PF, physical function; QL, global quality of life; RF, role function; SF, social function; SL, insomnia.
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complexity, paradoxically generating better fit indices for
less complex models. Therefore, selected models were
required to have at least an acceptable fit according to thethreshold values. Furthermore, all standardized factor load-
ings were required to be greater than 0.4 and statistically
significant [29]. Given that the data set included different
sources of data, we adjusted for the possible variability in
Table 1. Patient characteristics at baseline (before treatment;
n 5 3,282)
Age
Mean (SD) 58.9 (12.7)
Unknown 12.9%
Sex
Men 53.0%
Women 43.4%
Unknown 3.6%
Karnofsky status
Mean (SD) 85.6 (15.7)
Unknown 46.6%
Diagnosis
Head and neck 23.7%
Breast 17.4%
Prostate 13.0%
Esophagus/stomach 12.6%
Gynecological 11.1%
Lung 7.2%
Myeloma 3.0%
Colorectal 2.6%
Testicular 2.6%
Leukemia 2.1%
Other 4.7%
Stage
Locoregional (I and II) 27.6%
Advanced (III and IV and recurrence) 72.4%
Country
Norway 14.7%
Sri Lanka 13.2%
United Kingdom 8.9%
Spain 8.3%
Germany 8.2%
Netherlands 6.1%
Sweden 5.5%
France 5.2%
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account [10].
We used analysis of variance (ANOVA) to examine
known-groups validity, that is, the ability of the factor
score(s) derived from the best fitting higher order model,
and of the original QLQ-C30 scale scores to distinguish be-
tween groups known to be clinically different. We used tu-
mor stage (local vs. advanced) and performance status
(Karnofsky score 0-80 vs. 90-100) as grouping variables.
We evaluated responsiveness by comparing pretreatment
versus on-treatment QLQ-C30 scores. We calculated effect
sizes (ESs) using Cohen’s d statistic (mean difference
divided by the pooled standard deviation). These provide
a distribution-based estimate of the magnitude of mean dif-
ferences, where an ES of 0.2 is considered small, 0.5 mod-
erate, and 0.8 large [30].
We also generated relative validity (RV) estimates by
comparing the performance of higher order factor score(s)
with the original QLQ-C30 scale scores. The RV is the ratio
of the F-statistics derived from analysis of variance
comparing groups or time points. The RV indicates the rela-
tive difference in sample size needed to detect a statistically
significant difference inmean scores using the twomeasures.
More specifically, if the F-statistic ratio, in which the F-
statistic of the comparative scale is the numerator and the
F-statistic of a reference scale is the denominator (Fcomp:-
Fref), is greater than 1, then the comparative measure is
judged as performing better than the reference measure. In
the context of RV, ‘‘better performance’’ means that a small-
er sample size is required to detect amean difference [31,32].Belgium 4.4%
Canada 3.1%
USA 3.0%
Poland 2.6%
Turkey 2.6%
Other 14.1%
Study type
RCT 30.8%
Observational 31.8%
Psychometric 35.1%
Unknown 2.4%
Abbreviations: SD, standard deviation; RCT, randomized-controlled
trial.3. Results
3.1. Patient characteristics
Pretreatment data were available from 3,282 patients
(53.0% men; mean age 58.9 years). The most frequent di-
agnoses were head-and-neck cancer (23.7%), breast cancer
(17.4%), and prostate cancer (13.0%). Most patients
(72.4%) had an advanced tumor stage (UICC stage III or
IV). Pretreatment Karnofsky performance status data were
available for 53.5% of the sample (mean 5 85.6; SD
15.7). For further details, see Table 1.
Both pretreatment and on-treatment QLQ-C30 data and
information on the type of treatment were available for 811
patients (73.2% men; mean age 61.3 years). Of these pa-
tients, 35.1% were treated with chemotherapy, 30.0% with
radiotherapy, 28.6% had surgery, and 6.3% had another
type of treatment. Most common diagnoses were head-
and-neck cancer (31.6%), prostate cancer (34.6%), and
ovarian cancer (11.0%).
3.2. Modeling
Table 2 presents the fit indices for the seven models
tested. All models showed an acceptable fit, with thestandard model showing a good fit. With the exception
of the standard model, models 2 and 3 showed the best
fit. However, examination of the parameter estimates in
model 2 indicated that the standardized factor loadings
for the SL scale on physical health, and for the RF, FA,
and PA scale on mental health, were below the 0.4
threshold (0.02, 0.16, 0.15, and 0.16, respectively).
For model 3, the standardized factor loading of RF was
below 0.4 (0.255). These low factor loadings indicate
that these first-order factors might have to be excluded
from the model. In models 4 and 5, all factor loadings
were statistically significant and of moderate to strong
magnitude, providing support for the models. All
Table 2. Approximate goodness-of-fit indices for the higher order measurement models of the EORTC QLQ-C30
Model CFI TLI RMSEA Remarks
1. Standard 0.969 0.979 0.047
2. Physical/mental health and QL 0.943 0.971 0.056 Correlation between physical health and mental health 5 0.786
3. Physical burden/mental function and QL 0.944 0.970 0.057 Correlation between physical burden and mental function 5 0.424
4. Symptom burden, function and QL 0.932 0.966 0.061 Correlation between burden and function 5 0.564
5. HRQOL and QL 0.931 0.965 0.061
6. Formative symptom burden (free weights),
function, and QL
0.938 0.966 0.061 Correlation between formative burden and function 5 0.953
7. Formative symptom burden (fixed weights),
function, and QL
0.934 0.964 0.062 Correlation between formative burden and function 5 0.938
8. HRQOL including QL and FI 0.919 0.966 0.055
Abbreviations: CFI, Comparative Fit Index; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Ques-
tionnaire Core 30; FI, financial impact; HRQOL, health-related quality of life; RMSEA, root mean square error of approximation; TLI, Tucker-Lewis
Index; QL, global quality of life.
Table 3. (Un)standardized factor loadings for first-order factors
(EORTC QLQ-C30 scales) on the HRQOL higher order factor
Scale
HRQOL higher order factor
Unstandardized
factor loadings
Standardized
factor loadings
PF 1.000b 0.778a
SF 1.044 0.837a
RF 1.323 0.906a
EF 0.782 0.602a
CF 1.079 0.811a
FA 1.329 0.953a
NV 1.010 0.667a
PA 1.033 0.798a
DY 0.863 0.785a
SL 0.781 0.753a
AP 1.121 0.854a
CO 0.766 0.747a
DI 0.552 0.629a
Abbreviations: AP, appetite loss; CF, cognitive function; CFA,
confirmatory factor analysis; CO, constipation; DI, diarrhea; DY, dys-
pnea; EF, emotional function; EORTC QLQ-C30, European Organisa-
tion for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30; FA, fatigue; HRQOL, health-related quality
of life; NV, nausea and vomiting; PA, pain; PF, physical function;
QL, global quality of life; RF, role function; SF, social function; SL,
insomnia.
a P ! 0.01.
b Unstandardized factor loadings were fixed to 1.0 for model
identification.
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model 6 were greater than 0.4 and statistically significant.
However, for the formative symptom burden factor, only
FA had a standardized regression weight greater than
0.4. When fixing the weights for the formative scales on
the burden factor (model 7), all standardized regression
weights were far below the 0.4 threshold. In addition, in
both models, we found large correlations between the
higher order factors (Table 2), and in model 7, we found
a negative residual variance for item 19 (‘‘Did pain inter-
fere with your daily activities?’’; 0.009), which could
indicate identification problems suggesting the inappropri-
ateness of the model.
As in Gundy’s study, the modification indices (that esti-
mate the decrease in model chi square when freeing a fixed
parameter [33]) showed that item 22 (‘‘Did you worry?’’)
caused problems when fitting the models. We also observed
that the EF scale was associated with other scales not
captured by the fitted models.
When taking both fit indices and magnitude of factor
loadings into account, models 4 and 5 were the most prom-
ising. In the interest of parsimony and for conceptual rea-
sons (ie, function scales such as EF and CF include items
assessing symptoms), we decided to continue the analysis
with the less complex, single higher-order factor model 5
(Fig. 1 and Table 3).
Having selected the single-factor HRQOL model, we
investigated further if the model fit would be acceptable
if we were to include all 15 scales of the QLQ-C30 in
the model, including the global QL scale and the FI scale
that were excluded a priori by Gundy et al. (model 8 in
Fig. 1). Although this model showed an acceptable fit
(Table 2) and statistically significant standardized factor
loadings greater than 0.4, the results confirmed identifica-
tion problems (ie, a negative residual variance for one of
the items (‘‘Have you felt nauseated ?’’; 0.010), indi-
cating that the model does not work well.)
On the basis of these results, we generated a QLQ-C30
summary score, calculated as the mean of the combined 13
QLQ-C30 scale scores included in model 5 (excluding FI
and QL). For this purpose, all included scale scores werereversed so that higher scores represent better outcomes
(ie, better functioning or fewer symptoms).
3.3. Known-group comparisons and responsiveness
We investigated the ability of the QLQ-C30 summary
score to distinguish between groups formed on the basis
of tumor stage (stage IeII vs. IIIeIV) and Karnofsky per-
formance status (0e80 vs. 90e100), as compared to the
original 15 scale scores of the QLQ-C30. To calculate
RV, we used the QLQ-C30 summary score as the reference
value (ie, the denominator of this ratio).
Using tumor stage (Table 4) as the grouping variable, the
QLQ-C30 summary score showed the highest ES (0.65)
and RV, together with the fatigue scale (ES 5 0.64,
Table 4. Effect sizes and relative validities for the scales and summary
score of the EORTC QLQ-C30 using the known-group comparison
for tumor stage
Scale
Stage IeII,
N [ 907
Stage IIIeIV,
N [ 2,375
ES RVMean SD Mean SD
Summary score 84.2 14.3 73.0 18.3 0.65 1.00a
PF 84.4 18.7 73.6 24.1 0.47 0.53
SF 86.6 21.0 69.4 30.7 0.61 0.87
RF 81.5 26.4 61.3 35.5 0.61 0.88
EF 76.0 23.1 69.6 24.3 0.27 0.17
CF 86.2 19.0 80.6 22.4 0.26 0.16
QL 66.7 23.1 55.4 24.6 0.47 0.51
FA 23.5 23.5 40.9 28.7 0.64 0.97
NV 5.4 14.2 12.4 21.4 0.36 0.30
PA 18.0 23.2 35.4 31.9 0.58 0.81
DY 14.6 24.8 22.8 29.4 0.29 0.20
SL 24.2 29.8 31.6 32.7 0.23 0.13
AP 13.5 25.0 28.7 34.8 0.47 0.53
CO 13.5 23.3 23.7 32.0 0.34 0.27
DI 7.5 18.4 10.6 22.6 0.14 0.05
Abbreviations: AP, appetite loss; CF, cognitive function; CO, con-
stipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC
QLQ-C30, European Organisation for Research and Treatment of Can-
cer Quality of Life Questionnaire Core 30; ES, effect size; FA, fatigue;
NV, nausea and vomiting; PA, pain; PF, physical function; QL, global
quality of life; RF, role function; RV, Relative validity: performance of
the measures indicated as the ratio of the sample sizes required to
detect a mean difference with the measures being compared (ie,
scores less than 1.0 indicate better performance for the QLQ-C30
summary score); SD, standard deviation; SF, social function; SL,
insomnia.
a Reference score for calculating relative validity (ie, the ratio of
the F-statistics of the comparative score [numerator] and the refer-
ence score [denominator]).
Table 5. Effect sizes and relative validities for the scales and summary
score of the EORTC QLQ-C30 using the known-group comparison
for performance status
Scale
Karnofsky,
0e80,
N [ 693
Karnofsky,
90e100,
N [ 1,059
ES RVMean SD Mean SD
Summary score 62.0 18.1 83.7 14.8 1.34 1.00a
PF 60.5 25.6 87.0 16.4 1.29 0.93
SF 57.4 33.1 84.1 23.4 0.97 0.52
RF 39.7 36.4 80.8 27.2 1.32 0.97
EF 67.5 25.8 75.2 23.4 0.32 0.06
CF 72.5 26.4 87.2 18.8 0.66 0.25
QL 43.8 23.1 68.5 22.1 1.10 0.67
FA 56.5 28.5 25.3 25.1 1.18 0.77
NV 20.2 26.8 6.2 15.0 0.68 0.26
PA 50.6 34.5 19.3 25.4 1.07 0.63
DY 33.1 32.5 15.0 24.4 0.65 0.24
SL 35.5 34.9 25.0 30.4 0.33 0.06
AP 43.5 38.7 12.7 24.7 0.99 0.55
CO 35.6 35.9 13.7 25.7 0.73 0.29
DI 15.6 27.8 8.5 19.8 0.30 0.05
Abbreviations: AP, appetite loss; CF, cognitive function; CO, con-
stipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC
QLQ-C30, European Organisation for Research and Treatment of Can-
cer Quality of Life Questionnaire Core 30; ES, effect size; FA, fatigue;
NV, nausea and vomiting; PA, pain; PF, physical function; QL, global
quality of life; RF, role function; RV, Relative validity: performance of
the measures indicated as the ratio of the sample sizes required to
detect a mean difference with the measures being compared (ie,
scores less than 1.0 indicate better performance for the QLQ-C30
summary score); SD, standard deviation; SF, social function; SL,
insomnia.
a Reference score for calculating relative validity (ie, the ratio of
the F-statistics of the comparative score [numerator] and the refer-
ence score [denominator]).
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stantially lower ES of 0.47 and an RV of 0.51 when
compared to the QLQ-C30 summary score. Mean differ-
ences between patients with stage IeII and stage IIIeIV
were statistically significant for all scales (all P
values ! 0.001).
A similar pattern of results was found using performance
status as the grouping variable (Table 5). In this compari-
son, the QLQ-C30 summary score had the highest ES
(1.34), with the Role Functioning scale (ES 5 1.32,
RV 5 0.97) and the Physical Functioning scale
(ES 5 1.29, RV 5 0.93) performing nearly as well. Again,
the global QL scale was less discriminating, with an ES of
1.10 and an RVof 0.67. Mean differences between patients
with a low and high performance status (0e80 vs. 90e100)
were again statistically significant for all scales (all P
values ! 0.001).
In the longitudinal responsiveness analysis, only small
changes in HRQOL were observed in the 811 patients with
known-treatment type and pretreatment and on-treatment
QLQ-C30 data. With the exception of nausea/vomiting
(ES 5 0.34), all mean changes had ES’s less than 0.30
(with the lowest change found for global QL:ES 5 0.01). On the basis of these findings, we conducted
further responsiveness analyses for the radiotherapy group
only (n 5 244), as this group exhibited the most pro-
nounced score changes between the pretreatment and on-
treatment assessment (Table 6) and thus was considered
the most suitable subsample for this type of analysis. In this
radiotherapy group, the mean age was 65.6 years and
74.6% were female. Most common diagnoses were head-
and-neck cancer (33.3%), prostate cancer (37.9%), and
breast cancer (14.8%).
The comparison of patients before and during radio-
therapy showed the highest ES’s for individual symptom
scale scores (appetite loss ES 5 0.71; diarrhea
ES 5 0.68; nausea/vomiting, ES 5 0.66). The QLQ-C30
summary score had a somewhat lower ES (0.59) and
RV (1.00) compared to that of appetite loss RV (1.07),
but higher RV than that of nausea/vomiting (RV 5 0.81)
and diarrhea (RV 5 0.67). The global QL scale exhibited
substantially poorer responsiveness (ES 5 0.32,
RV 5 0.19). Changes in mean scores between the two time
points were statistically significant for all scales (all P
values ! 0.001).
Table 6. Effect sizes and relative validities for the scales and summary
score of the EORTC QLQ-C30 for responsiveness to change in
patients before and during radiotherapy
Scale
Pretreatment,
N [ 244
On-treatment,
N [ 244
ES RVMean SD Mean SD
Summary score 78.8 17.1 64.6 29.5 0.59 1.00a
PF 75.1 25.5 65.8 32.6 0.32 0.47
SF 79.4 26.6 67.7 35.3 0.37 0.35
RF 71.0 36.2 61.0 36.8 0.27 0.23
EF 75.7 24.7 62.7 31.9 0.46 0.40
CF 83.3 23.3 68.4 33.9 0.51 0.61
QL 59.5 24.6 51.8 23.6 0.32 0.19
FA 30.0 27.4 45.0 31.4 0.51 0.72
NV 7.8 17.4 25.7 34.5 0.66 0.81
PA 31.9 33.0 41.2 33.9 0.28 0.24
DY 19.1 27.9 30.2 35.8 0.35 0.28
SL 27.1 31.2 41.2 35.3 0.42 0.34
AP 15.7 26.9 39.4 38.6 0.71 1.07
CO 20.6 31.1 36.8 37.1 0.47 0.46
DI 7.2 17.8 26.3 35.4 0.68 0.67
Abbreviations: AP, appetite loss; CF, cognitive function; CO, con-
stipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC
QLQ-C30, European Organisation for Research and Treatment of Can-
cer Quality of Life Questionnaire Core 30; ES, effect size; FA, fatigue;
NV, nausea and vomiting; PA, pain; PF, physical function; QL, global
quality of life; RF, role function; RV, relative validity: performance of
the measures indicated as the ratio of the sample sizes required to
detect a mean difference with the measures being compared (ie,
scores less than 1.0 indicate better performance for the QLQ-C30
summary score); SD, standard deviation; SF, social function; SL,
insomnia.
a Reference score for calculating relative validity (ie, the ratio of
the F-statistics of the comparative score [numerator] and the refer-
ence score [denominator]).
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From the higher order HRQOL models originally intro-
duced by Gundy et al. [10], we have identified a single
higher-order factor model based on 27 of the 30 items of
the QLQ-C30 (excluding QL and FI) that exhibits good
model-data fit. The QLQ-C30 summary score derived from
this model is better than the original QLQ-C30 scales in
discriminating between groups known to be clinically
different. On the basis of the total patient sample, we were
unable to demonstrate that the summary scale performed
equally well or better than the individual QLQ-C30 scales
in terms of responsiveness to change over time. This was
likely due to the fact that, for the entire sample, it was diffi-
cult to detect significant change in QLQ-C30 scores over
time, regardless of which measure was used (the summary
scale or the original, individual scales). We were, however,
able to identify a subsample of patients, those receiving
radiotherapy, where significant change in the original
QLQ-C30 scale scores was observed. The observed respon-
siveness in the radiotherapy setting is something that one
would expect a priori. In the context of that subgroup anal-
ysis, the responsiveness of the summary scale was equal toor better than that of the original, individual scales of the
questionnaire.
The availability of this summary score for the QLQ-C30
provides a psychometrically more robust alternative to the
two-item overall QL scale score that is used frequently as
the primary HRQOL endpoint in observational studies
and clinical trials in oncology settings. Although model-
data fit was acceptable to good for all models proposed
by Gundy et al. [10], most two-factor models fell short of
the additional criterion we posed in this analysis, namely,
requiring the loadings to be greater than 0.40. The single-
factor HRQOL model including QL and FI exhibited
acceptable fit. Although this model may seem intuitively
attractive, it exhibited identification problems. These iden-
tification problems reflect the remark of Gundy et al. [10]
that including the two-item quality of life scale as an
explicit element of a higher order model is problematic
conceptually, and that the FI item should be omitted
because it is often excluded from analysis and reporting
of QLQ-C30 results. As pointed out in the results section,
the single higher order factor model, excluding QL and
FI, was preferred for statistical and conceptual reasons. It
also deals best with the potential problem of alpha error
inflation. In known-group comparisons and analysis of
responsiveness the newly developed QLQ-C30 summary
score outperformed or performed equally well as the indi-
vidual QLQ-C30 scales.
In an earlier attempt to develop a summary score for the
QLQ-C30, Hinz et al. [11] compared a functioning and
symptom summary score (comparable to our model 4)
against a single summary score comprising all 30 items.
On the basis of known-group comparisons, a single sum-
mary score was favored. As noted in the introduction,
Nordin et al. [12] found that the two-item QLQ-C30 quality
of life scale was not sensitive enough to detect group differ-
ences over time as opposed to three alternative summary
measures based on all or part of the QLQ-C30. However,
neither Hinz et al. nor Nordin et al. based their proposed,
alternative scoring algorithms on explicit conceptual con-
siderations; nor did they conduct formal testing of measure-
ment models using structural equation modeling or other
statistical techniques. In our view, a particular problem with
the scoring algorithm proposed by Hinz et al. is that it is
based on the scores of all individual items of the QLQ-
C30, rather than on scale scores. By doing so, they implic-
itly weighted the summary score such that those scales with
more items contributed more to the summary score than
those scales with fewer items. In contrast, our scoring
approach calculates the scale scores as the mean of the
summed items in a scale rather than as the sum of the items
in that scale. In this way, all scales are given equal weight
(importance). This scoring algorithm reflects the EORTC
Quality of Life Group’s decision to weigh all QLQ-C30
scales equally, regardless of the number of items in a scale.
The fact that some QLQ-C30 scales contain more items
than others reflects the complexity of the domain being
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domain than constipation), but not the importance attached
to the domain. Finally, as we noted in the methods section,
we initially examined an additional, 8th measurement
model for the QLQ-C30 that included all 15 scales. Howev-
er, those data could not be fitted into a single higher order
factor model.
The FACT-G, another widely used HRQOL question-
naire, also has a summary (or total) score. To the best of
our knowledge, the FACT-G total score is not based on
the results of higher order CFA. Nonetheless, known-
group comparisons and analyses of responsiveness
comparing the FACT-G total score to its individual scales
showed similar results to those of our study comparing
the QLQ-C30 summary score with the individual QLQ-
C30 scale scores [34,35].
King et al. [5] reported that the FACT-G total score out-
performed the two-item QLQ-C30 global QL scale score in
terms of both RV (0.31) and responsiveness to change over
time. In our analysis of responsiveness, the QLQ-C30
Global QL scale had an RV of only 0.18 when compared
to the QLQ-C30 summary score, suggesting a major gain
in responsiveness when using the summary score. These re-
sults are not surprising given that the FACT-G total score
and the QLQ-C30 summary score summarize data from a
larger set of items (both 27 items), whereas the EORTC
global QL scale score is based on only two items. It would
be of interest to compare the RV and responsiveness of the
FACT-G total score and the QLQ-C30 summary score.
The generalizability of our results is enhanced by the
fact that we had a very large and heterogeneous sample
of patients drawn from a number of participating countries.
There was some imbalance in the sample with regard to
diagnosis. However, as diagnosis was linked directly to
the patient samples contributed by the participating coun-
tries, we were able to compensate for this to some degree
by taking cluster sampling into account. Nevertheless, we
acknowledge that some patient populations (eg, head-and-
neck cancer) were overrepresented, and others may have
been underrepresented in our sample.Conclusion
In conclusion, our results provide empirical support for a
measurement model for the QLQ-C30 that yields a single
summary score based on 13 scales (27 items). The validity
and responsiveness of the new summary score is equal to,
and in many cases superior to the original, underlying
QLQ-C30 scale scores. Although not being a substitute
for the individual scales, the availability of the QLQ-C30
summary score can reduce the risk of type I errors that
can occur when making comparisons on the basis of the
15 outcomes generated by this questionnaire. In addition,
use of the QLQ-C30 summary score can reduce sample size
requirements. At the same time, there is some debate aboutthe appropriateness of using summary scores in certain
research contexts, for example, in confirmatory clinical tri-
als conducted to support product labeling claims [36,37].
However, these concerns may be more justified when a
summary score is created on an ad hoc basis for a particular
clinical trial. Ultimately, the research question and context
should drive decisions regarding the optimal level of ques-
tionnaire data aggregation or disaggregation.
Although further testing and use in both observational
studies and clinical trials is encouraged, the EORTC Qual-
ity of Life Group considers the current results to be suffi-
ciently robust to recommend, provisionally, the use of the
QLQ-C30 summary score to supplement the 15-outcome
profile generated by the QLQ-C30. The exact scoring algo-
rithm for generating the QLQ-C30 summary score is avail-
able via the group’s Web site, http://groups.eortc.be/qol.Acknowledgments
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